Drug intelligence / Profile preview

bifidobacterium animalis subsp. lactis cp-9 + lactobacillus johnsonii mh-68 + lactobacillus salivarius subsp. salicinius ap-32

Development stage: Unknown
Lead developer: Bioflag Biotech
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

This probiotic combination consists of three specific bacterial strains: *Lactobacillus salivarius* subsp. *salicinius* AP-32, *Lactobacillus johnsonii* MH-68, and *Bifidobacterium animalis* subsp. *lactis* CP-9. Developed by Bioflag Biotech, this live biotherapeutic product is being investigated for the treatment of Type 1 Diabetes Mellitus (T1DM). In clinical trials, the combination demonstrated the ability to modulate the gut microbiota, improve glycemic control (reducing HbA1c and fasting blood glucose), and regulate the immune response by decreasing pro-inflammatory cytokines (IL-8, TNF-α, IL-17, MIP-1β, and RANTES) and increasing anti-inflammatory TGF-β1. The strains were isolated from human gut and breast milk sources.

Other names: AP-32 + MH-68 + CP-9Lactobacillus salivarius subsp. salicinius AP-32 + Lactobacillus johnsonii MH-68 + Bifidobacterium animalis subsp. lactis CP-9

Beyond the preview

Go deeper on bifidobacterium animalis subsp. lactis cp-9 + lactobacillus johnsonii mh-68 + lactobacillus salivarius subsp. salicinius ap-32.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on bifidobacterium animalis subsp. lactis cp-9 + lactobacillus johnsonii mh-68 + lactobacillus salivarius subsp. salicinius ap-32.

Explore the full profile